8-KLeadership ChangesExhibits & Filings

ELI LILLY & Co 8-K Report, Executive Changes (Jul 8, 2013)

Filed July 8, 2013For Securities:LLY

Summary

Eli Lilly & Company (LLY) filed an 8-K on July 8, 2013, to announce the return of its Chairman, President, and CEO, John Lechleiter, Ph.D., from a medical leave of absence. Dr. Lechleiter resumed his executive duties on July 8, 2013, after being on leave since May 6, 2013. This transition signals a return to stable leadership for the company. During Dr. Lechleiter's absence, Derica W. Rice served as acting CEO and will now return to his role as Executive Vice President, Global Services and Chief Financial Officer. Additionally, Ellen R. Marram, who acted as interim chairperson of the Board, will revert to her position as the board's lead independent director. The company also furnished a press release detailing these changes as an exhibit to this filing.

Key Highlights

  • 1John Lechleiter, Ph.D., has resumed his roles as Chairman, President, and CEO of Eli Lilly & Company.
  • 2Dr. Lechleiter's return follows a medical leave of absence that began on May 6, 2013.
  • 3Derica W. Rice will return to his previous position as Executive Vice President, Global Services and Chief Financial Officer.
  • 4Rice had been serving as acting CEO during Dr. Lechleiter's leave.
  • 5Ellen R. Marram will resume her role as the Board's Lead Independent Director.
  • 6Marram had been serving as interim Chairperson of the Board.
  • 7The company furnished a press release (Exhibit 99.1) detailing these leadership changes.

Frequently Asked Questions

The primary purpose of this 8-K filing is to announce the return of Eli Lilly's CEO, John Lechleiter, Ph.D., from a medical leave of absence and the subsequent adjustments in interim leadership roles.

During Dr. Lechleiter's medical leave, Derica W. Rice served as acting CEO and will now return to his role as Executive Vice President, Global Services and Chief Financial Officer. Ellen R. Marram, who served as interim chairperson of the Board of Directors, will resume her position as the board's lead independent director.

Dr. Lechleiter's medical leave of absence began on May 6, 2013, and he resumed his duties as Chairman, President, and CEO on July 8, 2013.

No, this 8-K filing is solely focused on leadership changes due to Dr. Lechleiter's return from medical leave. It does not contain new financial statements or operational updates beyond the personnel changes.